clinical-gastroenterology-digestive-diseases2017-posters

Volume 7, Issue 6 (Suppl)

J Gastrointest Dig Syst, an open access journal

ISSN: 2161-069X

Page 64

December 07-08, 2017 Madrid, Spain

International Conference on Clinical Gastroenterology & Hepatology

International Conference on Digestive Diseases

CO-ORGANIZED EVENT

J Gastrointest Dig Syst 2017, 7:6(Suppl)

DOI: 10.4172/2161-069X-C1-059

Serum biomarker panel (GastroPanel

) and slow-release L-cysteine (Acetium

Capsule): Rational for

the primary prevention of gastric cancer

Kari J Syrjanen

Biohit HealthCare, Finland

Statement of the Problem:

The major risk factors of gastric cancer (GC) are Helicobacter pylori (HP) infection and atrophic

gastritis (AG). It is possible to diagnose HP-infection and AG by serological testing with panel of biomarkers (GastroPanel®,

Biohit Oyj, Finland): pepsinogen I (PGI), pepsinogen II (PGII), gastrin-17 (G-17) and HP-antibodies. Severe AG leads to

acid-free stomach colonized by HP and other bacteria, producing acetaldehyde (Group I human carcinogen; IARC). Together

with other conditions leading to acid-free stomach, or those exposing the subjects to increased concentrations of acetaldehyde,

these subjects are at high-risk for gastric and esophageal cancer.

Methodology & Theoretical Orientation:

GastroPanel® is the first non-invasive diagnostic tool for dyspeptic symptoms,

and for screening of asymptomatic subjects for the risks of GC. A novel formulation (Acetium® Capsule, Biohit) based on

slow-release L-cysteine, designed to protect the stomach in these high-risk subjects by its capacity to eliminate carcinogenic

acetaldehyde.

Findings:

The test results test are interpreted by a specially designed software (GastroSoft®) identifying eight diagnostic marker

profiles. Of those, four represent purely functional disorders, while three others specify structural abnormalities, and one is

typical to HP-infection. Its superb clinical performance was validated in two recent meta-analysis, and the test has excellent

longitudinal predictive values for incident GC. Acetium® Capsule is a unique medical device designed to elimination of

carcinogenic acetaldehyde in the stomach among the high-risk subjects: AG associated with HP infection; autoimmune AG;

cigarette smokers; alcohol consumers; chronic users of PPI medication, and those 500 million people in Asia with mutated

ALDH2 enzyme exposed to higher local concentrations of acetaldehyde.

Conclusion & Significance:

With a rational use of these two medical devices, one can diagnose the gastric high-risk conditions

and subsequently protect the stomach against acetaldehyde exposure.